BDBM305283 US10144734, Example 299::US10172845, Example 299::US10441581, Example 299::US10881652, Example 299::US11648243, Example 299

SMILES CC(C)(O)COc1cc(-c2ccc(nc2)N2CCC(C)(CC2)C(=O)Nc2c(F)cccc2F)c2c(cnn2c1)C#N

InChI Key InChIKey=IHNUDZDIJJMKEW-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 305283   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305283(US10144734, Example 299 | US10172845, Example 299 ...)
Affinity DataIC50:  6.80nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305283(US10144734, Example 299 | US10172845, Example 299 ...)
Affinity DataIC50:  14.9nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305283(US10144734, Example 299 | US10172845, Example 299 ...)
Affinity DataIC50:  6.80nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305283(US10144734, Example 299 | US10172845, Example 299 ...)
Affinity DataIC50:  14.9nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE-TK assay tech...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305283(US10144734, Example 299 | US10172845, Example 299 ...)
Affinity DataIC50:  14.9nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE™-TK assay tec...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810R](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305283(US10144734, Example 299 | US10172845, Example 299 ...)
Affinity DataIC50:  14.9nMAssay Description:The potency of a compound inhibiting G810R mutant RET kinase was determined using CisBio's HTRF Kinease-TK assay technology. The assays contained...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305283(US10144734, Example 299 | US10172845, Example 299 ...)
Affinity DataIC50:  6.80nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305283(US10144734, Example 299 | US10172845, Example 299 ...)
Affinity DataIC50:  14.9nMAssay Description:Wildtype and V804M mutant: Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305283(US10144734, Example 299 | US10172845, Example 299 ...)
Affinity DataIC50:  6.80nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF® KinEASE™-TK assay tec...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [658-1114,V804M](Homo sapiens (Human))
Array Biopharma

US Patent
LigandPNGBDBM305283(US10144734, Example 299 | US10172845, Example 299 ...)
Affinity DataIC50:  6.80nMAssay Description:Compounds of Formula I were screened for their ability to inhibit wildtype and V804M mutant RET kinase using CisBio's HTRF KinEASE-TK assay techn...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent